Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vaccine composition, preparation method and application thereof

A vaccine composition and immunogenicity technology, applied in the field of vaccine compositions, can solve the problems of increased stress response of pigs, increased risk of infection, complicated operation procedures, etc., to avoid adverse reactions and to last for a long immunization period. , the effect of simplifying the immunization program

Active Publication Date: 2014-09-17
PU LIKE BIO ENG
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantages of the existing vaccines are that they need to be immunized in stages, at least two injections are needed to prevent multisystem syndrome in weaned piglets and reproductive disorders in sows, the cost is high, and the operation procedures are cumbersome, which increases the risk of infection and causes pig The stress response of the herd increases, which may lead to problems such as immune failure in some herds
However, an unanticipated problem with combination vaccines is the recent recognition that one vaccine in combination vaccines may have an adverse effect on the other, the so-called "antigen interference effect"
It has been found that when two existing vaccines are simply mixed, one or both may lose their potency (see patent application CN101035559A)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition, preparation method and application thereof
  • Vaccine composition, preparation method and application thereof
  • Vaccine composition, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1, Porcine Circovirus, Porcine Japanese Encephalitis Virus and Porcine Parvovirus Triple Inactivated Vaccine Composition, Preparation and Inspection of Porcine Japanese Encephalitis Virus and Porcine Parvovirus Dual Vaccine

[0039] 1. The source of the virus strain

[0040] The PCV2 virus used in the PCV2-PPV-JEV triple vaccine in the embodiments of the present invention is the PCV2 SH strain, and the JEV strain used in the PCV2-PPV-JEV triple vaccine and the PPV-JEV double vaccine in the embodiments of the present invention is The SD-2011 strain, the PPV strain used in the PCV2-PPV-JEV triple vaccine and the PPV-JEV dual vaccine in the embodiment of the present invention is the HN-2011 strain.

[0041] 2. Preparation and inspection of vaccine semi-finished products

[0042] 2.1 Preparation of poisonous seeds for production

[0043] 2.1.1 Preparation of porcine circovirus type 2 SH strain:

[0044] Properly dilute the virus seed of PCV2 SH strain with virus ...

Embodiment 2

[0113] Example 2, this study is to evaluate the immune efficacy of PCV2-PPV-JEV combination triple vaccine with different antigen content and PPV-JEV dual vaccine and PCV2 single vaccine

[0114] 1. Test material

[0115] According to the method in embodiment 1, prepare PCV2-PPV-JEV triple vaccine (PCV2 antigen content is 10 6.0 TCID 50 / ml, PPV is 10 6.0 TCID 50 / ml, JEV is 10 6.0 TCID 50 / ml), recorded as vaccine L; PCV2-PPV-JEV triple vaccine (PCV2 antigen content is 10 6.5 TCID 50 / ml, PPV antigen content is 10 7.0 TCID 50 / ml, JEV antigen content is 10 7.0 TCID 50 / ml), recorded as vaccine M; PCV2-PPV-JEV triple vaccine (PCV2 antigen content is 10 7.0 TCID 50 / ml, PPV antigen content is 10 8.0 TCID 50 / ml, JEV antigen content is 10 8.0 TCID 50 / ml), recorded as vaccine H; low-dose PCV2-PPV-JEV triple vaccine (PCV2 antigen content is 5×10 5.5 TCID 50 / ml, PPV antigen content is 10 7.0 TCID 50 / ml, JEV antigen content is 10 7.0 TCID 50 / ml), recorded a...

Embodiment 3

[0144] Example 3. This study is to evaluate the reproductive performance and growth performance of piglets after PCV2-PPV-JEV triple combination vaccine and PPV-JEV dual vaccine combined with PCV2 single vaccine immunized sows

[0145] 1. Test material

[0146] According to the method in embodiment 1, prepare PCV2-PPV-JEV triple vaccine (PCV2 antigen content is 10 6.5 TCID 50 / ml, PPV antigen content is 10 7.0 TCID 50 / ml, JEV antigen content is 10 7.0 TCID 50 / ml), recorded as vaccine M; PCV2 inactivated vaccine (PCV2 antigen content is 10 6.5 TCID 50 / ml) is recorded as vaccine 2; PPV-JEV dual vaccine (PPV antigen content is 10 7.0 TCID 50 / ml, JEV antigen content is 10 7.0 TCID 50 / ml) was recorded as vaccine 3.

[0147] 2. Design of animal experiments

[0148] 2.1 Design of challenge experiment: 30 gilts were selected and divided into 3 groups with 10 gilts in each group. Before immunization, blood was collected from sows in each group for detection of viremia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a vaccine composition, a preparation method and an application thereof. The vaccine composition includes: an immune dose of porcine circovirus 2-type antigen, an immune dose of porcine Japanese encephalitis virus antigen, an immune dose of porcine parvovirus antigen and an adjuvant. The vaccine composition can effectively prevent and cure postweaning piglet multisystemic syndrome and sow reproduction dysfunctional diseases which are caused by 2-type porcine circovirus, porcine Japanese encephalitis virus and porcine parvovirus. An immune effect of the vaccine composition is better than that of a single vaccine. The vaccine composition is little in side effects, is high in valence of a serum antibody, has a long immune period, can save time and labor intensity, has a small stress response to a pig, can simplify immunity processes and can reduce production cost and prevention cost.

Description

technical field [0001] The invention relates to a vaccine composition capable of preventing and treating multisystem syndrome of weaned piglets and reproductive disorder diseases of sows. Background technique [0002] Porcine circovirus disease or porcine circovirus-associated disease is an immunosuppressive disease mainly caused by porcine circovirus type 2 (Porcine circovirus 2, PCV2), manifested as post-weaning piglet multisystem failure syndrome, porcine dermatitis nephropathy Syndrome, porcine respiratory disease syndrome, reproductive failure, piglet myocarditis, hyperplastic and necrotizing pneumonia and central nervous system diseases, etc. Porcine circovirus mainly infects piglets aged 5-12 weeks. The main clinical manifestations are weight loss, dyspnea, jaundice, interstitial pneumonia, lymphadenopathy, hepatitis and nephritis, etc.; histopathological damage is mainly characterized by apoptosis. Characteristic systemic loss of lymphocytes and predominant infiltra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/23A61P31/14A61P31/20A61P15/08A61K39/12
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com